• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 144 filed by Allakos Inc.

    9/6/24 3:53:16 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ALLK alert in real time by email
    Form 144 Filer Information UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    Form 144

    NOTICE OF PROPOSED SALE OF SECURITIES
    PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933

    FORM 144

    144: Filer Information

    Filer CIK
    0001398311
    Filer CCC
    XXXXXXXX
    Is this a LIVE or TEST Filing? Radio button checked LIVE Radio button not checked TEST

    Submission Contact Information

    Name
    Phone
    E-Mail Address

    144: Issuer Information

    Name of Issuer
    Allakos Inc.
    SEC File Number
    001-38582
    Address of Issuer
    825 INDUSTRIAL ROAD
    SUITE 500
    SAN CARLOS
    CALIFORNIA
    94070
    Phone
    650-597-5002
    Name of Person for Whose Account the Securities are To Be Sold
    Radford Harlan Baird
    See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

    Relationship to Issuer
    Officer

    144: Securities Information

    Title of the Class of Securities To Be SoldName and Address of the BrokerNumber of Shares or Other Units To Be SoldAggregate Market ValueNumber of Shares or Other Units OutstandingApproximate Date of SaleName the Securities Exchange
    Common
    Fidelity Brokerage Services LLC
    900 Salem Street
    Smithfield � RI � 02917
    136658808.458885071309/06/2024
    NASDAQ


    Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

    144: Securities To Be Sold

    Title of the ClassDate you AcquiredNature of Acquisition TransactionName of Person from Whom AcquiredIs this a Gift?Date Donor AcquiredAmount of Securities AcquiredDate of PaymentNature of Payment *
    Common09/03/2024Restricted Stock VestingIssuerCheckbox not checked1366509/03/2024Compensation

    * If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



    Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

    144: Securities Sold During The Past 3 Months

    Name and Address of SellerTitle of Securities SoldDate of SaleAmount of Securities SoldGross Proceeds
    Harlan Radford III
    825 Industrial Road
    Suite 500
    San Carlos � CA � 94070
    Common06/28/20248706487857.12

    144: Remarks and Signature

    Remarks
    Sale includes an amount necessary to cover a tax obligation resulting from the settlement of a vested equity award distribution.
    Date of Notice
    09/06/2024

    ATTENTION:

    The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
    Signature
    /s/ Emily Navaro, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Harlan Radford III.

    ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

    Get the next $ALLK alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLK

    DatePrice TargetRatingAnalyst
    1/17/2024$6.00 → $1.50Buy → Hold
    Jefferies
    1/16/2024Overweight → Neutral
    Cantor Fitzgerald
    12/18/2023Mkt Perform → Outperform
    William Blair
    12/8/2023$9.00 → $6.00Buy
    Jefferies
    9/27/2023$11.00Mkt Outperform
    JMP Securities
    5/12/2023$6.00 → $9.00Hold → Buy
    Jefferies
    3/7/2023$22.00Overweight
    Piper Sandler
    9/12/2022$2.00Neutral → Underperform
    SMBC Nikko
    More analyst ratings

    $ALLK
    SEC Filings

    View All

    SEC Form 15-12G filed by Allakos Inc.

    15-12G - Allakos Inc. (0001564824) (Filer)

    5/27/25 9:00:14 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Allakos Inc.

    SCHEDULE 13G/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 6:42:25 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Allakos Inc.

    SCHEDULE 13D/A - Allakos Inc. (0001564824) (Subject)

    5/19/25 4:15:11 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Allakos downgraded by Jefferies with a new price target

    Jefferies downgraded Allakos from Buy to Hold and set a new price target of $1.50 from $6.00 previously

    1/17/24 7:08:59 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos downgraded by Cantor Fitzgerald

    Cantor Fitzgerald downgraded Allakos from Overweight to Neutral

    1/16/24 1:35:19 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos upgraded by William Blair

    William Blair upgraded Allakos from Mkt Perform to Outperform

    12/18/23 6:44:17 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Allakos Inc. Enters into Agreement to Be Acquired by Concentra Biosciences, LLC for $0.33 in Cash per Share

    SAN CARLOS, Calif., April 02, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. ("Allakos") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced it has entered into a definitive merger agreement (the "Merger Agreement") whereby Concentra Biosciences, LLC ( "Concentra") will acquire Allakos for $0.33 in cash per share of Allakos common stock ("Allakos Common Stock"). Allakos' Board of Directors has unanimously determined that the acquisition by Concentra is in the best interests of all Allakos shareholders and, following the unanimous recommendation of Allakos' Transaction Committee, has appro

    4/2/25 8:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial Results

    SAN CARLOS, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company that has been developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter ended December 31, 2024. Recent Allakos Events Reported topline data from the Phase 1 study of AK006 in patients with chronic spontaneous urticaria in January 2025.Announced in January 2025 that the Company was discontinuing further development of AK006, restructuring operations to reduce costs and exploring strategic alternatives. Cash Guidance Allakos ended the fourth qua

    3/12/25 4:02:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Bvf Partners L P/Il returned 16,312,872 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/19/25 6:45:29 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Walker Paul Edward returned 6,147,260 shares to the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:28:27 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    President Tomasi Adam returned 533,420 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Allakos Inc. (0001564824) (Issuer)

    5/15/25 4:08:04 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Financials

    Live finance-specific insights

    View All

    Allakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces Restructuring

    – AK006 did not demonstrate therapeutic activity in CSU –– Allakos will discontinue further development of AK006, reduce workforce by 75% and explore strategic alternatives –– Management to host conference call and webcast today at 8:30 am E.T. – SAN CARLOS, Calif., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Allakos Inc. (Company) (NASDAQ:ALLK), today announced topline results from its phase 1 clinical trial of AK006 in chronic spontaneous urticaria (CSU). "While AK006 was well tolerated, we are disappointed that the preclinical inhibitory effects observed did not translate to clinical benefit in patients with CSU. As a result, the Company has decided to discontinue further clinical developme

    1/27/25 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces a Restructuring to Focus on Development of AK006

    Existing cash to fund planned ongoing operations into mid-2026AK006 is being tested in a comprehensive Phase 1 clinical program, including: ongoing single and multiple ascending dose trial in healthy volunteersa randomized, double-blind, placebo-controlled trial in patients with CSUa subcutaneous AK006 Phase 1 PK and bioavailability trial Management to host conference call and webcast today at 8:00 am E.T. SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the Company) (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced a restructuring to reduce costs and to focus on AK006 c

    1/16/24 7:02:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Announces Phase 2 Lirentelimab Trials in Atopic Dermatitis and Chronic Spontaneous Urticaria Did Not Meet Their Primary Endpoints

    – Allakos plans not to pursue further development of lirentelimab; will focus on AK006 clinical development and additional preclinical programs – – Management to host conference call and webcast today at 8:00 am E.T. – SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Allakos Inc. (the "Company") (NASDAQ:ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today announced topline data from its phase 2 clinical trial in patients with atopic dermatitis (ATLAS) and from its Phase 2b clinical trial in patients with chronic spontaneous urticaria (MAVERICK). "We are disappointed that these trials did not m

    1/16/24 7:00:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Leadership Updates

    Live Leadership Updates

    View All

    Lycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology Pipeline

    SOUTH SAN FRANCISCO, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Lycia Therapeutics, Inc., a biotechnology company developing lysosomal targeting chimera (LYTAC)-based protein degradation therapies to eliminate disease at its source, today announced the appointment of Chin Lee, M.D., M.P.H., as its chief medical officer. Dr. Lee brings more than 20 years of clinical research and development experience, advancing therapies from early stage to commercialization. He will oversee the company's clinical, nonclinical and regulatory functions and the advancement of its pipeline of LYTAC degraders. Lycia's proprietary LYTAC platform enables the rapid, deep and selective depletion of extracellular

    2/11/25 11:30:00 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Neil Graham to its Board of Directors

    SAN CARLOS, Calif., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Neil Graham, M.D. to the Allakos board of directors. Dr. Graham was the Chief Medical Officer of Tiziana Life Sciences Limited and currently serves on the board of directors of Aslan Pharmaceuticals Limited, Pharmaxis Limited and Zura Bio Limited. Among other experiences, Dr. Graham was the Vice President of Strategic Program Direction, Immunology and Inflammation at Regeneron Ph

    8/30/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Allakos Appoints Rand Sutherland and Dolca Thomas to its Board of Directors

    SAN CARLOS, Calif., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (NASDAQ:ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory receptors present on immune effector cells involved in allergy, inflammatory and proliferative diseases, today announced the appointment of Rand Sutherland, M.D. and Dolca Thomas, M.D. to the Allakos board of directors. Dr. Sutherland was the Chief Executive Officer of Seeker Biologics, a privately-held company, and currently serves on the board of directors of Krystal Biotech, Inc. and Vanqua Bio, Inc. Among other experiences, Dr. Sutherland held senior roles developing therapeutics at Translate Bio, Inc. as well

    8/2/23 4:05:00 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Allakos Inc.

    SC 13G - Allakos Inc. (0001564824) (Subject)

    11/12/24 9:50:12 AM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Allakos Inc.

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    7/8/24 4:32:41 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Allakos Inc. (Amendment)

    SC 13G/A - Allakos Inc. (0001564824) (Subject)

    2/14/24 4:58:16 PM ET
    $ALLK
    Biotechnology: Pharmaceutical Preparations
    Health Care